Monetizing its transformation

Last week's deal with Roche for E2F discovery programs in cancer is a key step in ArQule Inc.'s continued transformation from one-time combichem play to oncology product company. The deal provides ARQL with both funding and its partner's expertise in oncology development and marketing, which ARQL hopes will help pave the way to

Read the full 536 word article

How to gain access

Continue reading with a
two-week free trial.